Abstract:Background and aims To analyze the effect of oral metformin on changes in gut microbiota characteristics and metabolite composition in normal weight type 2 diabetic patients. Methods T2DM patients in the cross-sectional study were given metformin for 12 weeks. Patients with unmedicated T2DM were used as a control group to observe the metrics of T2DM patients treated with metformin regimen. 16S rDNA high-throughput gene sequencing of fecal gut microbiota of the study subjects was performed by llumina NovaSeq6000 platform. Targeted macro-metabolomics was performed on 14 cases of each of the gut microbiota metabolites of the study subjects using UPLC-MS/MS technology. Correlations between the characteristics of the gut microbiota and its metabolites, basic human parameters, glycolipid metabolism indicators, and inflammatory factors were analyzed using spearman analysis. Results Glycolipid metabolism indexes and inflammatory factors were higher in normal-weight T2DM patients than in the healthy population (P<0.05), but body weight, BMI, waist circumference, and inflammatory factor concentrations were lower in normal-weight T2DM patients than in obese T2DM patients (P<0.05). Treatment with metformin in T2DM patients improved glycolipid metabolism, but the recovery of glycolipid metabolism was more pronounced in obese T2DM patients. None of the differences in α-diversity indexes were statistically significant (P>0.05), and the differences in β-diversity were statistically significant (P <0.05). Community diversity and species richness recovered after metformin intervention compared to before, and were closer to the healthy population. We found that Anaerostipes/Xylose/Ribulose/Xylulose may play an important role in the treatment of normal-weight T2DM with metformin by improving glycemic lipids and reducing inflammation. And Metformin may play a role in obese T2DM through Romboutsia, medium-chain fatty acids (octanoic acid, decanoic acid, and dodecanoic acid). Conclusion Gut microbial dysbiosis and metabolic disorders were closely related to glucose-lipid metabolism and systemic inflammatory response in normal-weight T2DM patients. Metformin treatment improved glucose metabolism levels, systemic inflammation levels in T2DM patients, closer to the state of healthy population. This effect may be mediated by influencing the gut microbiota and microbial host co-metabolites, mainly associated with Anaerostipes and xylose/Ribulose/Xylulose. Metformin may exert its effects through different pathways in normal-weight versus obese T2DM patients.

Combination of Oligofructose and Metformin Alters the Gut Microbiota and Improves Metabolic Profiles, Contributing to the Potentiated Therapeutic Effects on Diet-Induced Obese Animals

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

Treating Obesity Using the Combination of Metformin and Epigallocatechin-3-gallate

Modulation Of Gut Microbiota By Berberine And Metformin During The Treatment Of High-Fat Diet-Induced Obesity In Rats

Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in <i>db/db</i> mice

Comparative Evaluation of the Effect of Metformin and Insulin on Gut Microbiota and Metabolome Profiles of Type 2 Diabetic Rats Induced by the Combination of Streptozotocin and High-Fat Diet

Effect of Metformin on the Urinary Metabolites of Diet-Induced-obese Mice Studied by Ultra Performance Liquid Chromatography Coupled to Time-of-flight Mass Spectrometry (UPLC-TOF/MS).

Effects Of Metformin Combined With Lactoferrin On Lipid Accumulation And Metabolism In Mice Fed With High-Fat Diet

Metformin increases tauroursodeoxycholic acid levels to improve insulin resistance in diet-induced obese mice

Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice

The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes

Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone

Prebiotic Mannan-Oligosaccharides Augment the Hypoglycemic Effects of Metformin in Correlation with Modulating Gut Microbiota

Metformin modulates the gut microbiome in a mice model of high-fat diet-induced glycolipid metabolism disorder

The Combined Effect of Metformin and Mirabegron on Diet‐induced Obesity

Effect of oral metformin on gut microbiota characteristics and metabolite fractions in normal-weight type 2 diabetic mellitus patients

Ginsenoside Rb1, salvianolic acid B and their combination modulate gut microbiota and improve glucolipid metabolism in high-fat diet induced obese mice

Impact And Consequences Of Polyphenols And Fructooligosaccharide Interplay On Gut Microbiota In Rats

Tauroursodeoxycholic acid functions as a critical effector mediating insulin sensitization of metformin in obese mice

Astragalus compound oral solution synergistically enhances health-promoting effect of metformin in type 2 diabetes mouse model

Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice